Investors File Class Action Against BioAge Labs Following Troubling Trial News
LOS ANGELES, Jan. 20, 2025 /PRNewswire/ — The Schall Law Firm, known for its work in shareholder rights litigation, has initiated a class action lawsuit against BioAge Labs, Inc. (“BioAge” or “the Company”) BIOA for allegedly violating federal securities laws.
Investors who bought BioAge’s securities during its initial public offering (“IPO”) on September 26, 2024, are urged to contact the firm before March 10, 2025.
If you are a shareholder experiencing losses, click here to participate.
For further details, reach out to Brian Schall at the Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or call 310-301-3335. Additional contact options include the firm’s website at www.schallfirm.com, or email at bschall@schallfirm.com.
Currently, the class has yet to be certified. Until that time, investors are not represented by an attorney. If you opt for no action, you will remain an absent class member.
The Complaint alleges that the Company misled investors. On December 6, 2024, BioAge announced the discontinuation of its ongoing STRIDES Phase 2 trial for its lead candidate, azelaprag. The Company attributed this decision to safety concerns among participants, contradicting earlier claims made during its IPO that azelaprag had promising potential for treating obesity with incretin drugs. These misleading statements, according to the Complaint, resulted in investor losses once the truth was revealed.
Join the case to recover potential losses.
The Schall Law Firm specializes in representing investors globally in securities class action lawsuits and related litigation.
This press release could be considered Attorney Advertising in some jurisdictions under applicable legal and ethical standards.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/bioa-investors-have-opportunity-to-lead-bioage-labs-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302355032.html
SOURCE The Schall Law Firm
Market News and Data brought to you by Benzinga APIs
